The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | SEER-based analysis: higher second primary malignancy risk in Hispanic and API DLBCL survivors
Pallawi Torka, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses findings from a SEER-based analysis showing a higher risk of second primary malignancies among Asian/Pacific Islander (API) and Hispanic survivors of diffuse large B-cell lymphoma (DLBCL). Dr Torka highlights that these findings are exploratory and may impact follow-up of DLBCL survivors. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This, you know, the work you are referring to was led by my friend Dr Advani and it was pretty fascinating because we, when we look at disparities, we rarely study other populations like Pacific Islanders and we found that they actually have a higher incidence of secondary malignancies if they survive their diffuse large B-cell lymphoma. I think there’s a lot to be parsed out there. I’m not really sure how the data translates to older patients in general...
This, you know, the work you are referring to was led by my friend Dr Advani and it was pretty fascinating because we, when we look at disparities, we rarely study other populations like Pacific Islanders and we found that they actually have a higher incidence of secondary malignancies if they survive their diffuse large B-cell lymphoma. I think there’s a lot to be parsed out there. I’m not really sure how the data translates to older patients in general. But it just tells us that maybe we are putting too much burden on some patients by calling them every three months in their follow-up phase. And maybe there are some patients we need to be calling more than that. But I think right now, it’s hard to make any recommendations based on this exploratory SEER database analysis.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
